» Authors » Jamshed Dalal

Jamshed Dalal

Explore the profile of Jamshed Dalal including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 49
Citations 161
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Mohan J, Roy D, Ray S, Dalal J, Sharma K, Kumar A, et al.
J Assoc Physicians India . 2024 Oct; 72(10):83-90. PMID: 39390868
Background: Management of essential hypertension (HTN) remains challenging, with contemporary control being achieved in <1/10 of the cases, especially when aligned with the recently updated guidelines of American College of...
2.
Kaul U, Dalal J, Hiremath J, Seth S, Mehta A, Juvale N, et al.
J Assoc Physicians India . 2024 Oct; 72(10):63-68. PMID: 39390864
Heart failure (HF) is a condition that can result in repeated hospitalizations every year and can result in worsening HF (WHF). Although current pharmacological treatment for HF is fairly effective,...
3.
Dalal J, Guha S, Reddy Y, Ponde C, Shrivastava S, Badani R, et al.
J Assoc Physicians India . 2024 May; 71(12):56-61. PMID: 38736055
Introduction: Hypertension (HTN) remains one of the most important risk factors for cardiovascular (CV) diseases and a leading cause of mortality worldwide. Despite improvement in detection and treatment, poor blood...
4.
Sawhney J, Ramakrishnan S, Madan K, Ray S, Jayagopal P, Prabhakaran D, et al.
Indian Heart J . 2023 Dec; 76 Suppl 1:S6-S19. PMID: 38052658
Dyslipidemias are the most important coronary artery disease (CAD) risk factor. Proper management of dyslipidemia is crucial to control the epidemic of premature CAD in India. Cardiological Society of India...
5.
Dalal J, Chandra P, Chawla R, Kumar V, Abdullakutty J, Natarajan V, et al.
Drugs Real World Outcomes . 2023 Dec; 11(1):167-176. PMID: 38038836
Background: Coexisting hypertension, type 2 diabetes mellitus (T2DM), and dyslipidemia (triple disease) can lead to greater risk of cardiovascular morbidity and mortality. The present study sought to comprehend the prevalence,...
6.
Dalal J, Dutta A, Hiremath J, Iyengar S, Mohan J, Ooman A, et al.
Cardiol Ther . 2023 Nov; 12(4):557-570. PMID: 37947939
This manuscript aims to critically evaluate the current evidence regarding adverse cardiovascular effects associated with proton pump inhibitors (PPIs) in patients with coronary artery disease (CAD). It also provides guidance...
7.
Rajput R, Mohan J, Sawhney J, Dalal J, Mullasari A, Vasnawala H, et al.
Indian Heart J . 2023 Oct; 75(6):436-442. PMID: 37884126
Objective: Type 2 diabetes mellitus (T2DM) is known to be associated with development of left ventricular (LV) dysfunction and heart failure (HF). The study aimed to determine the prevalence of...
8.
Dalal J, Chandra P, Ray S, Hazra P, Hiremath J, Kumar V, et al.
Cardiol Ther . 2023 Jun; 12(3):445-471. PMID: 37382802
Heart failure is a significant public health concern characterized by notable rates of morbidity and mortality. Despite the presence of guideline-directed medical therapy (GDMT), its utilization remains inadequate. This practical...
9.
Mohan J, Dalal J, Chopra V, Narasimhan C, Kerkar P, Oomman A, et al.
Indian Heart J . 2022 Nov; 74(6):441-449. PMID: 36410415
Transthyretin cardiac amyloidosis (ATTR-CM) is a rare and under-recognized disorder characterized by the aggregation of transthyretin-derived insoluble amyloid fibrils in the myocardium. Heterogeneity of symptoms at presentation, makes its diagnosis...
10.
Mohan V, Singh A, Zargar A, Almeida A, Bhalla A, Mohan J, et al.
Diabetes Metab Syndr . 2022 Nov; 16(12):102661. PMID: 36375366
Background And Aim: The interplay between cardiovascular disease (CVD), chronic kidney disease (CKD) and type 2 diabetes (T2D) is well established. We aim at providing an evidence-based expert opinion regarding...